You're probably wondering where success will come from, when this technology has been overshadowed with failures and few, if any successes.
Gene therapy needs more work, time, patience and money.
Not only is Cell Genesys involved in gene therapy and cancer vaccines but, Cell Genesys originally developed Abgenix' technology, maker of humanized monoclonal antibodies. In 1996, Cell Genesys formed Abgenix and increased shareholders' value through this spinout, which has grown from a wholly owned subsidiary of Cell Genesys to a Nasdaq 100 company in less than five years. There is the possibility and the technology has potential. A paper was published in the journal Science back in October 2000 that showed very encouraging results with gene therapy on aged monkeys who have Parkinson's disease. It is successes like this one that keep the medical researchers and investors believing gene therapy can work some day.